Molecular subtyping revealed that HER2-negative, HER2-positive, and triple-negative breast cancers were almost equally represented, with percentages of 35.4%, 32.1%, and 32.5%, respectively. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.